Risk for Progression to Severe COVID-19 Lower With Nirmatrelvir + Ritonavir
Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir linked to 89 percent lower risk for progression versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.